[
    [
        {
            "time": "",
            "original_text": "国盛证券维持贝达药业买入评级：Q1在去年高基数的前提下，依然实现稳健增长，超出市场预期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "买入评级",
                    "Q1",
                    "稳健增长",
                    "超出预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券维持贝达药业买入评级：Q1在去年高基数的前提下，依然实现稳健增长，超出市场预期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：第一季度盈利1.48亿人民币，同比增长13.24%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "第一季度",
                    "盈利",
                    "同比增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：第一季度盈利1.48亿人民币，同比增长13.24%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【华西医药崔文亮团队】?《贝达药业点评报告：产品线快速丰富，抗肿瘤领域全面拓展》",
            "features": {
                "keywords": [
                    "贝达药业",
                    "产品线",
                    "抗肿瘤",
                    "拓展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华西医药崔文亮团队】?《贝达药业点评报告：产品线快速丰富，抗肿瘤领域全面拓展》",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业涨2.06%报109.84元 创近1个多月新高",
            "features": {
                "keywords": [
                    "贝达药业",
                    "涨",
                    "新高"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业涨2.06%报109.84元 创近1个多月新高",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "九州药业(603456)2020年年报及2021年一季报点评：业绩略超我们预期 CDMO业务驱动公司业绩高速增长",
            "features": {
                "keywords": [
                    "九州药业",
                    "年报",
                    "一季报",
                    "CDMO",
                    "业绩增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "九州药业(603456)2020年年报及2021年一季报点评：业绩略超我们预期 CDMO业务驱动公司业绩高速增长",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：业绩符合预期 恩沙替尼开始放量",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩",
                    "恩沙替尼",
                    "放量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩符合预期 恩沙替尼开始放量",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "每日“药”闻| 百济神州泽布替尼疗效超伊布替尼；微创医疗去年营收同比下滑18%",
            "features": {
                "keywords": [
                    "百济神州",
                    "泽布替尼",
                    "疗效",
                    "微创医疗",
                    "营收下滑"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "每日“药”闻| 百济神州泽布替尼疗效超伊布替尼；微创医疗去年营收同比下滑18%",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "达伯舒Q1业绩公布；华东医药10天内又一交易，动作频频；恒瑞1类新药上市申请获受理",
            "features": {
                "keywords": [
                    "达伯舒",
                    "Q1",
                    "业绩",
                    "华东医药",
                    "恒瑞",
                    "新药",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "达伯舒Q1业绩公布；华东医药10天内又一交易，动作频频；恒瑞1类新药上市申请获受理",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]